Skip to main
ACLX

Arcellx (ACLX) Stock Forecast & Price Target

Arcellx (ACLX) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 7%
Hold 79%
Sell 0%
Strong Sell 0%

Bulls say

Arcellx Inc. exhibits a robust commercial advantage through its collaboration with Gilead, which provides access to advanced CAR-T cell therapy manufacturing and patient support, thereby enhancing its market position in the oncology sector. The promising clinical profile of Arcellx’s Anito-cel therapy for multiple myeloma, showing durability comparable to established CAR-T treatments, supports a significant potential sales estimate of $7 billion as broader label expansions may follow. The strategic partnership with Kite positions the company favorably for profitability as Arcellx approaches anticipated regulatory approval and a successful market entry, further validating its growth trajectory and shareholder value creation.

Bears say

Arcellx Inc. faces significant risks that contribute to a negative outlook for its stock, primarily stemming from uncertainties surrounding its clinical programs and the recent acquisition proposal from Gilead Sciences, valued at $7.8 billion. The company may struggle to produce additional successful therapies from its D-Domain CAR-T and ARC-SparX platforms, leading to potential commercial challenges, heightened competition, and insurance pricing pressures. Furthermore, the complexity of the acquisition, along with clinical, regulatory, and financing risks, raises concerns about the stability and future value of Arcellx's stock.

Arcellx (ACLX) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 7% recommend Buy, 79% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcellx (ACLX) Forecast

Analysts have given Arcellx (ACLX) a Hold based on their latest research and market trends.

According to 14 analysts, Arcellx (ACLX) has a Hold consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcellx (ACLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.